Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "IDA"

2178 News Found

Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
News | January 25, 2026

Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr

Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025


Cipla reports consolidated PAT of Rs. 675.80 Cr
News | January 24, 2026

Cipla reports consolidated PAT of Rs. 675.80 Cr

Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025


Laurus Labs reports consolidated Q3 net profit of Rs. 251.66 Cr
News | January 24, 2026

Laurus Labs reports consolidated Q3 net profit of Rs. 251.66 Cr

Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025


Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
News | January 23, 2026

Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025


Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr
News | January 21, 2026

Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025


FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts
News | January 16, 2026

FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts

The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts


Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility
R&D | January 12, 2026

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants


Novartis to open Florida radioligand facility
News | January 12, 2026

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US


Merck completes acquisition of Cidara Therapeutics
News | January 07, 2026

Merck completes acquisition of Cidara Therapeutics

Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market